Nabriva Therapeutics (NBRV)
4.59
-0.13 -2.75%
NASDAQ
Apr 25, 20:00
Delayed 2m
USD
View All Key Stats
NBRV Key Stats
| Income Statement | |
| Revenue (TTM) | 5.319M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.49 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -74.36M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -1.98K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 168.53M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 25.74 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 2.054 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -24.11M |
| Return on Equity (TTM) | Upgrade |
View All NBRV News
NBRV News
-
WireHeadlineTime (ET)
-
Globe Newswire04/25 07:00
-
PR Newswire04/20 10:17
-
SA Breaking News04/13 09:56
-
Globe Newswire04/13 07:00
-
MT Newswires04/09 16:24
-
SA Breaking News04/09 16:20
-
Yahoo03/29 07:50
-
MT Newswires03/27 08:57
-
SA Breaking News03/27 07:25
-
Globe Newswire03/27 07:00
View All Events
NBRV Events
| Date | Type | Description |
|---|---|---|
| 11/09/2018 | Misc | Nabriva Therapeutics PLC Third Quarter Earnings Conference Call in 2018 |
| 11/16/2017 | Earnings | Nabriva Therapeutics PLC Third Quarter Earnings Results in 2017 |
| 11/09/2017 | Earnings | Nabriva Therapeutics PLC Third Quarter Earnings in 2017 Release |
| 11/09/2017 | Misc | Nabriva Therapeutics PLC Third Quarter Earnings Conference Call in 2017 |
| 08/07/2017 | Earnings | Nabriva Therapeutics PLC Second Quarter Earnings Results in 2017 |
| 06/26/2017 | Splits | Ratio: 10:1 |
NBRV Fundamentals
Income Statement View Statement
NBRV Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
NBRV One Page Reports
- One Page Report Download
NBRV Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 4.59 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.nabriva.com
- Investor Relations URL: N/A
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: N/A
- Next Earnings Release: N/A
- Last Earnings Release: Nov. 16, 2017
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.
NBRV Excel Add-In Codes
- Name: =YCI("NBRV","name")
- Description: =YCI("NBRV","description")
- Sector: =YCI("NBRV","sector")
- Industry: =YCI("NBRV","industry")
- Est. Current Fiscal Year End: =YCI("NBRV","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other NBRV Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- NBRV Tweets Stocktwits
Advertisement
